);
Contact

News

Posted on
LinkedIn Post 1
March 2026

Fertiga contributes to the Aurora Blastocyst study at UZ Gent

At Fertiga, we are proud to contribute to the Aurora Blastocyst study, led by University Hospital Ghent (UZ Gent) and Prof. Dr. Dominic Stoop.

In current IVF/ICSI practice, embryo selection is primarily based on morphological assessment, which remains inherently subjective. In some regions, invasive techniques such as Preimplantation Genetic Testing for Aneuploidy (PGT-A) are used, highlighting the need for objective, non-invasive alternatives.

The Aurora Test is a non-invasive preimplantation test performed on cumulus cells surrounding the oocyte. Using RNA expression profiling, it evaluates oocyte competence and supports embryo selection. Fertiga nv performs the Aurora analysis upon receipt of patient cumulus cells.

This study compares morphology-based selection with selection supported by the Aurora Test in day-5 single embryo transfer, assessing its impact on clinical pregnancy and live birth rates.

Posted on
LinkedIn Post 1
December 2025

Fertiga took the stage at MEFS2025 in Dubai

Last weekend at Middle East Fertility Society (MEFS) 2025 in Dubai, Tom Adriaenssens from Fertiga took the stage to present the latest research on the Aurora Test — a breakthrough using cumulus cell–derived gene expression models to predict blastocyst development in ICSI patients

📍 Scientific Session 18: Reproductive Medicine — Track 3

🗓 Saturday, Dec 6, 2025 | ⏰ 14:30–16:10 (+04) | 🏛 Al Wasel

Missed it? Catch the session details and explore the future of reproductive medicine here:

Posted on
LinkedIn Post 1
December 2025

Fertiga is ready for MEFS Dubai!

We’re excited to be here at the Middle East Fertility Society (MEFS) 32nd Annual Scientific Meeting from 4-6 December 2025 at the Grand Hyatt Dubai.

💡 Visit Tom Adriaenssens and Johan Smitz at Booth 29 to connect and discover how we’re pushing the boundaries of fertility innovation with our Aurora Test.

Posted on
LinkedIn Post 1
November 2025

🔬✨ New Publication Alert ✨

We are proud to share our latest scientific contribution published in Reproductive Biology and Endocrinology:

📌 “Live birth in patients stimulated with r-hFSH or r-hFSH: r-hLH is strongly associated with cumulus cell derived gene expression models”

We would like to thank our colleagues from Brussels IVF for their fruitful collaboration in this clinical study.

Our findings highlight the clinical use of cumulus cells as a predictive tool for embryo prioritization for improving the live birth rate with the first transfer.

At Fertiga we remain committed to translating research into better outcomes for all patients with our motto ‘one try, one child’.

This study was sponsored by Fertiga NV and supported by Merck KGaA, Darmstadt, Germany.

Posted on
LinkedIn Post 1
November 2025

Fertiga at Innovations in Reproductive Medicine 2030 in Valencia!

Elien Van Hecke attended the conference of “Innovations in Reproductive Medicine 2030” in Valencia on 20-21 November. Women’s health, femtech and more specific fertility treatments are fields with lots of opportunities. Thank you Carlos Simon Foundation to organize this conference and bringing business, investors and innovations together.

📊 She also presented our latest poster entitled: “Cumulus cell gene expression is associated with the development of a transferable blastocyst in ICSI patients stimulated with r-hFSH or r-hFSH:r-hLH.”

Posted on
LinkedIn Post 1
October 2025

All eyes on Fertiga in Women’s Health Week Europe 2025!

We’re thrilled to announce that Fertiga is selected to pitch at the Med Device & Therapeutics Innovation Showcase during Women’s Health Week Europe 2025 on 17 October!

Our presentation in the ‘Clinical, Diagnostic, or Treatment-based’ category will spotlight how Fertiga is redefining fertility care through science and innovation. A fantastic opportunity to connect with investors, pharma leaders, and health systems shaping the future of women’s health. 🌍💡

Read more

Posted on
LinkedIn Post 1
October 2025

Fertiga is attending BioJapan 2025 and Japan Society of Assisted Reproduction!

We’re proud to share that Elien Van Hecke, CCO at Fertiga, will be present in Yokohama at BioJapan 2025 (October 8-10) to connect with partners, discuss the future of fertility biotech, and showcase our pioneering work in IVF innovation. Looking forward to inspiring conversations and new collaborations! ✨

Nontheless, Fertiga is honored to be present at the Japan Society of Assisted Reproduction. Elien Van Hecke will engage with the reproductive medicine community and highlight our commitment to advancing fertility biotech and IVF innovation. Looking forward to meaningful exchanges and future collaborations!🌍

Read more

Posted on
LinkedIn Post 1
July 2025

Fertiga at the 41st ESHRE Annual Meeting in Paris, France

Fertiga, in collaboration with Brussels IVF and Merck KGaA, Darmstadt, Germany, has announced ground-breaking results from the AURORA-REC study on gene expression in ICSI patients treated with r-hFSH or r-hFSH & r-hLH. During AURORA-REC study we evaluated the differences in cumulus cell gene expression between two types of ovarian stimulation and proved that gene-based algorithms can predict live birth in these patient groups:

  • the accuracy achieved for women stimulated with r-hFSH was 69%
  • the accuracy achieved for women stimulated with r-hFSH & r-hLH was 88%

Posted on
July 2025

Fertiga teams up with Fertilab Barcelona in AURORA-Donor study

Suppressing the pituitary gland is essential during ovarian stimulation. Traditionally done via daily GnRH-antagonist injections, this study compared that approach to an alternative: using oral progesterone (Medroxyprogesterone). The key takeaways from the AURORA-Donor study so far:

  1. Both protocols are equally effective in egg maturation, fertilization, blastocyst development, and genetic quality (euploidy).
  2. No significant difference in hormonal levels or stimulation duration, but the progesterone protocol is:
  • 💰 40x more cost-efficient
  • 💊 More patient-friendly (oral vs. daily injections)
  • 🧑‍⚕️ Easier for clinics to manage.

The next step? Exploring gene expression in cumulus cells to better predict outcomes like live birth – stay tuned for more from the AURORA-Donor study!

Posted on
LinkedIn Post 1
May 2025

All eyes on Fertiga in EMD Serono Corporate Accelerator!

We’re thrilled to share that Fertiga has been selected to pitch at Women’s Health Week (previously SiS) in New York 2025 as part of the EMD Serono Corporate Accelerator (ESCA)! It’s an honour to join a select group of innovators driving change in reproductive health, with the support of EMD Serono, Inc. and M Ventures.


EN
EN